Hans Christian Hagedorn

Hans Christian Hagedorn was a pioneering Danish physician who co-founded the Nordisk Insulinlaboratorium in 1923. His defining moment was the development of the first prolonged-acting insulin formulations, which transformed insulin from a life-saving but short-acting emergency treatment into a manageable chronic therapy. This decision established the company's long-term philosophy of focusing on peptide chemistry and formulation science to improve patient compliance.

Hans Christian Hagedorn was a Danish physician and researcher who played a pivotal role in the introduction of insulin to Scandinavia. After meeting Frederick Banting in Canada in 1923, Hagedorn worked with August Krogh to establish the Nordisk Insulinlaboratorium in Copenhagen. His background in clinical medicine gave him a unique perspective on the practical challenges of diabetes management, driving his focus on developing insulin formulations that required less frequent injections. During his tenure, he oversaw the development of protamine insulin and NPH insulin, which became the standard of care for diabetes treatment for decades. Hagedorn was also known for his commitment to making insulin affordable and accessible to all patients, a philosophy that remains core to Novo Nordisk's corporate culture. Despite the commercial success of the company, Hagedorn maintained a modest lifestyle and donated a significant portion of his wealth to medical research. He is widely respected in Denmark for his role in transforming diabetes from a fatal diagnosis into a manageable chronic condition.